|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Pathophysiology and biology of peritoneal carcinomatosis显示文摘Peritoneal carcinomatosis represents a devastating form of cancer progression with a very poor prognosis.Its complex pathogenesis is represented by a dynamic process comprising several steps.To the best of our knowledge pathogenesis can be partly explained by 3 major molecular pathways: (1) dissemination from the primary tumor;(2) primary tumor of peritoneum;and (3) independent origins of the primary tumor and peritoneal implants.These are not mutually exclusive and combinations of different mechanisms could occur inside a single case.There are still several aspects which need explanation by future studies.A comprehensive understanding of molecular events involved in peritoneal carcinomatosis is of paramount importance and should be systematically pursued not only to identify novel strategies for the prevention of the condition,but also to obtain therapeutic advances,through the identification of surrogate markers of prognosis and development of future molecular targeted therapies. | Shigeki Kusamura Dario Baratti Nadia Zaffaroni Raffaella Villa Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 8 |
| 2 | Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement显示文摘 | J. Esquivel R. Sticca P. Sugarbaker E. Levine T. D. Yan R. Alexander D. Baratti D. Bartlett R. Barone P. Barrios S. Bieligk P. Bretcha-Boix C. K. Chang F. Chu Q. Chu S. Daniel E. Bree M. Deraco L. Dominguez-Parra D. Elias R. Flynn J. Foster A. Garofalo F. | 2007 | Annals of Surgical Oncology2007，，1： | 4 |
| 3 | Early and long-term postoperative management following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy显示文摘Peritoneal surface malignancies have been traditionally regarded as end-stage conditions amenable to merely palliative options. The combination of aggressive cytoreductive surgery (CRS), involving peritonectomy procedures and multivisceral resections, with intra-operative hyperthermic intra-peritoneal chemotherapy (HIPEC) and/or early postoperative intra-peritoneal chemotherapy (EPIC) to treat the microscopic residual tumor is a new concept. In recent years, promising results have been reported for peritoneal mesothelioma and carcinomatosis of gastrointestinal and gynaecologic origin treated by this combined protocol. However, CRS with HIPEC and/or EPIC is a complex procedure associated with high rates of potentially life-threatening complications. Furthermore, disease progression following comprehensive treatment is not uncommon and represents a relevant cause of treatment failure. The present paper reviews the available information on early postoperative management and long-term follow-up in patients treated with CRS and intraperitoneal chemotherapy. The peculiar clinical and biological alterations that can be expected during an uncomplicated postoperative course, as compared to standard digestive surgery, are discussed. Early recognition and appropriate management of the most common adverse events are addressed, in order to minimize the impact of treatment-related morbidity on survival and quality of life results. Since re-operative surgery with additional HIPEC, has proven to be useful in selected patients with recurrent disease, long-term surveillance aiming at early detection of postoperative disease progression has become a relevant issue. Current results on follow-up investigations are presented. | Dario Baratti Shigeki Kusamura Barbara Laterza Maria Rosaria Balestra Marcello Deraco | 2010 | World Journal of Gastrointestinal Oncology2010，2，1： | 4 |
| 4 | Experience with peritoneal mesothelioma at the Milan National Cancer Institute显示文摘Diffuse malignant peritoneal mesothelioma (DMPM) is an uncommon and rapidly fatal tumor.Therapeutic options have traditionally been limited and ineffective.The biologic and molecular events correlated with poor responsiveness to therapy are still poorly understood.In recent years,an innovative treatment approach involving aggressive cytoreductive surgery (CRS) and perioperative intraperitoneal chemotherapy has reportedly resulted in improved outcome,as compared to historical controls.Since 1995,at the National Cancer Institute (NCI) of Milan (Italy),patients with DMPM have been treated with CRS and hyperthermic intraperitoneal chemotherapy (HIPEC).In the present paper,clinical experiences and basic science investigations on DMPM at Milan NCI are reviewed.Perioperative and long-term outcome results with CRS and HIPEC are presented.Clinico-pathological prognostic factors were investigated by multivariate analysis.The pathologic features and immunohistochemical markers related to DMPM biologic behavior were assessed in a large case-series uniformly treated at our institution.The prevalence and prognostic role of telomere maintenance mechanisms,which account for the limitless cell replicative potential of many malignancies,were studied.The dysregulation of the apoptotic pathways may play a role in the relative chemo-resistance of DMPM and a better understanding of apoptosis-related mechanisms could result in novel targeted therapeutic strategies.On this basis,the expression of survivin and other IAP family members (IAP-1,IAP-2,and X-IAP),the pro-apoptotic protein Smac/DIABLO,and antigens associated with cell proliferation (Ki-67) and apoptosis (caspase-cleaved cytokeratin-18) were analyzed.Finally,analyses of EGFR,PDGFRA and PDGFRB were performed to ascertain if deregulation of RTK could offer useful alternative therapeutic targets. | Marcello Deraco Dario Baratti Antonello Domenico Cabras Nadia Zaffaroni Federica Perrone Raffaella Villa Jenny Jocollè Maria Rosaria Balestra Shigeki Kusamura Barbara Laterza Silvana Pilotti | 2010 | World Journal of Gastrointestinal Oncology2010，2，2： | 3 |
| 5 | Diffuse Malignant Peritoneal Mesothelioma: Failure Analysis Following Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)显示文摘 | D. Baratti MD S. Kusamura MD PhD A. D. Cabras MD P. Dileo MD B. Laterza MD M. Deraco MD | 2009 | Annals of Surgical Oncology2009，，2： | 2 |
| 6 | Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion显示文摘 | Marcello Deraco MD Daisuke Nonaka MD Dario Baratti MD Paolo Casali MD Juan Rosai MD Rami Younan MD Andreola Salvatore MD Antonello D. Cabras AD MD Shigeki Kusamura MD | 2006 | Annals of Surgical Oncology2006，，2： | 2 |
| 7 | Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei显示文摘 | Marcello Deraco Dario Baratti Maria Grazia Inglese Biagino Allaria Salvatore Andreola Cecilia Gavazzi Shigeki Kusamura | 2004 | Annals of Surgical Oncology2004，，： | 2 |
| 8 | Prognostic Value of Circulating Tumor Markers in Patients with Pseudomyxoma Peritonei Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy显示文摘 | Dario Baratti MD Shigeki Kusamura MD PhD Antonia Martinetti MD Ettore Seregni MD Barbara Laterza MD Daniela G. Oliva MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，8： | 2 |
| 9 | Cytoreductive surgery and hyper- thermic intraperitoneal chemotherapy (H1PEC) in the treatment of pseu- domyxoma peritonei: ten years experi- ence in a single center 显示文摘 | Deraco M Kusamura S Laterza B et a | 2006 | In Vivo2006，20，6： | 1 |
| 10 | Cytoreductive surgery followed be intraperitoneal hyperthermic perfusion in the treatment of recurrent epithelial ovarian cancer: a phase Ⅱ clinical study显示文摘 | Rossi CR Pennacchioli E | 2001 | Tumori2001，87，3： | 1 |
| 11 | Impact of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Systemic Toxicity显示文摘 | Shigeki Kusamura MD PhD Dario Baratti MD Rami Younan MD Barbara Laterza MD Grazia Daniela Oliva MD Pasqualina Costanzo MD Myriam Favaro MD Cecilia Gavazzi MD Federica Grosso MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，9： | 1 |
| 12 | Prognostic analysis of elinicopathologic factors in 49 patients with diffuse malignant peritoneal mesothelioma treated with cytoreductive surgery and intraperitoneal hyperthermic perfusion显示文摘 | Deraco M Nonaka D Baratti D | 2006 | Ann Surg Oncol2006，13，2： | 1 |
| 13 | Circulating CA125 in Patients with Peritoneal Mesothelioma Treated with Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion显示文摘 | Dario Baratti MD Shigeki Kusamura MD Antonia Martinetti MD Ettore Seregni MD Daniela G. Oliva MD Barbara Laterza MD Marcello Deraco MD | 2007 | Annals of Surgical Oncology2007，，2： | 1 |
| 14 | Peritoneal earcinomatosis;feature of dissemination, a review 显示文摘 | Deraco M Santoro N Carraro O | 1999 | Tumori1999，85，1： | 1 |
| 15 | Cytoreductive surgery and hy perthermic intraperitoneal chemotherapy as upfront therapy for ad- vanced epithelial ovarian cancer: multi-institutional phase-II trial 显示文摘 | Deraco M Kusamura S Virz S | 2011 | Gynecol Oncol2011，122，2： | 1 |
| 16 | Updated treatment of peritoneal carcinomas: a review 显示文摘 | Deraco M Laterza B Kusamura S | 2007 | Minerva Chir2007，62，6： | 1 |
| 17 | Bowel Complications in 203 Cases of Peritoneal Surface Malignancies Treated With Peritonectomy and Closed-Technique Intraperitoneal Hyperthermic Perfusion显示文摘 | Rami Younan MD Shigeki Kusamura MD Dario Baratti MD Grazia Daniela Oliva MD Pasqualina Costanzo MD Myriam Favaro MD Cecilia Gavazzi MD Marcello Deraco MD | 2005 | Annals of Surgical Oncology2005，，11： | 1 |
| 18 | Cytoreductive sur- gery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi - institutional phase - I1 trial显示文摘 | DERACO M KUSAMURA S VIRZI S | 2011 | Gynecol Oncol2011，122，2： | 1 |
| 19 | Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis:clinical outcome and prognostic factors in 60 consecutive patients显示文摘 | Rossi C R Deraco M De Simone M | 2004 | Cancer2004，100，9： | 1 |
| 20 | Peritoneal mesothelioma treated by induction chemotherapy,cytoreductive surgery,and intraperitoneal hyperthemfic perfusion显示文摘 | Deraco M Casali P Inglese MG | | 0，，03： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员